基线容积多参数MR成像对经动脉化疗栓塞治疗神经内分泌肝转移瘤的预后价值
回顾性纳入84例接受TACE治疗的神经内分泌肝转移瘤患者,在基线MR上测量肿瘤体积及动脉强化、静脉强化和ADC的容积参数。优势瘤体积≥73 cm³及容积平均AE≥45%、VE≥73%是OS和HPFS的独立预后因素,ADC无预后价值;评估多个病灶与单个病灶预后价值相似。
要点
- 基线优势瘤体积≥73 cm³、容积平均AE≥45%、VE≥73%与TACE后OS和HPFS独立相关。
- 容积平均ADC高低两组OS和HPFS相似,ADC未见预后价值。
- 评估最多1个、2个或5个指数病灶,预后价值相似。
核心结论
- 基线MR上优势病灶的容积强化值和肿瘤体积可能作为接受TACE治疗的NELMs患者OS和HPFS的预后因素。
研究设计与样本
- 回顾性研究,纳入84例接受TACE治疗的神经内分泌肝转移瘤患者,在基线MR成像上测量肿瘤体积及动脉强化、静脉强化和ADC的容积参数,每例患者最多选取1个、2个和5个指数病灶,OS为主要终点、HPFS为次要终点。
诊断标准与关键数值
- 多因素生存分析显示,基线优势瘤体积≥73 cm³、容积平均AE≥45%、容积平均VE≥73%为OS的独立预后因素,HR分别为2.73(95%CI 1.45, 5.15)、0.32(95%CI 0.17, 0.63)、0.35(95%CI 0.17, 0.72),并为HPFS的独立预后因素,HR分别为2.30(95%CI 1.38, 3.84)、0.46(95%CI 0.25, 0.84)、0.36(95%CI 0.19, 0.57);容积平均ADC低组与高组OS和HPFS相似。
临床应用与阅片要点
- 阅片时可测量优势病灶的容积肿瘤体积及容积平均AE、VE,用于TACE治疗的NELMs患者预后评估;评估多个病灶较单个病灶未提供额外信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether baseline multiparametric MR imaging can predict overall survival (OS) and hepatic progression-free survival (HPFS) in patients with neuroendocrine liver metastases (NELMs) treated with transarterial chemoembolization (TACE).
METHODS: This retrospective study included 84 NELMs patients treated with TACE. Tumor volume and volumetric measurements of arterial enhancement (AE), venous enhancement (VE), and apparent diffusion coefficient (ADC) were performed on baseline MR imaging. A maximum of one, two, and five index lesions were selected in each patient. OS was the primary endpoint and HPFS was the secondary endpoint. Prognostic values of volumetric multiparametric MR parameters for predicting OS and HPFS considering a maximum of one, two, and five index lesions were assessed.
RESULTS: Prognostic values of volumetric multiparametric MR parameters for predicting OS and HPFS were similar regardless of the maximum number of index lesions. Multivariate survival analysis showed that baseline dominant tumor volume ≥ 73 cm3, volumetric mean AE ≥ 45%, and mean VE ≥ 73% were independent prognostic factors for OS (HR 2.73; 95% CI 1.45, 5.15; HR 0.32; 95% CI 0.17, 0.63; HR 0.35; 95% CI 0.17, 0.72, respectively) and HPFS (HR 2.30, 95% CI 1.38, 3.84; HR 0.46, 95% CI 0.25, 0.84; HR 0.36, 95% CI 0.19, 0.57, respectively). OS and HPFS were similar in patients with low and high volumetric mean ADC.
CONCLUSION: Volumetric enhancement values and tumor volume of the dominant lesion on baseline MR imaging may act as prognostic factors for OS and HPFS in NELMs patients treated with TACE.
KEY POINTS: • High volumetric mean AE and VE, and low tumor volume of the dominant lesion on baseline MR imaging were associated with favorable OS and HPFS in NELMs patients treated with TACE. • Evaluation of multiple lesions does not provide additional information as compared to single lesion evaluation.
引用
- Luo Y, Pandey A, Ghasabeh MA, et al. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019. PMID: 30877462. doi:10.1007/s00330-019-06100-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。